Small Molecule API Market to Gain Pace as Government Spending on Novel Biologics Research Increases: FMI
In terms of production, over 50% of small molecule active pharmaceutical ingredient (API) is outsourced.
DUBAI, UAE / ACCESSWIRE / April 22, 2021 / Future Market Insights’ global small molecule active pharmaceutical ingredient (API) market report forecasts a prolific nudge through 2021, as increasing demand of high potency drugs and increasing chronic diseases boosts the market demand. Rising cancer cases and increasing demand for effective diagnosis and R&D for oncology procedures is accelerating the growth of small molecule API market.
Furthermore, rising government reimbursement policies and funding to develop small molecule oncology drugs is spurring the growth of market. Rapid development in technologies for long-term delivery of medication in molecule type is aiding the growth for small molecule API market. Driven by these factors, the market is poised to expand at the rate of 5% CAGR through 2021.
For instance, chronic disease such as diabetes, asthma, cancer, are significantly rising across the globe. According to the report of International Diabetes Federation, around 463 million people in 2019 were diagnosed with diabetes and new cancer cases are expected to grow by 23.6 million by 2030. Hence, rising incidence of various chronic disease are providing growth opportunities for manufacturing companies.
“Increasing research on small molecule APIs and novel biologics is expected to drive the market demand,” remarks the FMI analyst.
Request a report sample with 255 pages to gain comprehensive insights at https://www.futuremarketinsights.com/reports/sample/rep-gb-4591
Key Takeaways
- Standard API will hold the maximum share of over 79.6% through 2021
- Oncology segmented is expected to be the lucrative segment, accounting for 26.6% market share
- Commercial application account for greater grater sales of small molecule API
- China is estimated to remain one of the most lucrative market for small molecule, exhibiting growth of 5.5% CAGR
- India is expected to emerge as a lucrative market backed by increasing manufacturing in pharmaceutical industry
- Germany to retain its dominance in European small molecule API market, accounting for over 30% sales
Prominent Drivers
- Technological advancements in API manufacturing and growing importance of generics are key factors driving market demand
- Growing adoption of AI-based tools for drug discovery is expected to propel the market growth
- Investment in small molecule API drug discovery from pharmaceutical companies is likely to improve the demand
- Growing demand for newly developed small molecule drugs in manufacturing industry is expected to improve the demand
Key Restraints
- Increasing penetration of counterfeit drugs is likely to restrict the growth of small molecule API market
Contact Sales for Further Assistance in Purchasing this Report@ https://www.futuremarketinsights.com/checkout/4591
Competitive Landscape
Some of the leading companies profiled by FMI operating in small molecule API market include Pfizer Inc., Johnson Matthey, Nanjing King-Friend Biochemical Pharmaceutical Co. Ltd., Sanofi SA, Novartis AG, Bristol-Myers Squibb, Boehringer Ingelheim GmbH, GlaxoSmithKline PLC, Albany Molecular Research Inc., AstraZeneca, BASF SE, and Teva Pharmaceuticals among others. According to the report, the market is highly competitive. Manufacturers in small molecule API market are aiming for strategic collaborations and R&D activities.
For instance, recently Lonza Pharma & Biotech, a leading player announced the launch of its pharmaceutical early intermediates cGMP and APIs supply. This initiative leveraged chemical production facilities at the company’s Visp to address global early-intermediates supply security and quality concerns.
Also, in March 2021, BridGene Biosciences, a biotechnology company using cutting edge tools to discover and develop small molecules for hard-to-drug therapeutics targets, announced a strategic research collaboration and licensing agreement with Takeda Pharmaceutical Company Limited.
Furthermore, on 1st April 2021, Fusion Pharmaceutical Inc., announced the acquisition of Ipsen’s intellectual property and assets related to IPN-1087, a small molecule targeting neurotensin receptor 1, NTSR1.
More Insights on FMI’s Bentonite Market
The latest market study by Future Market Insights offers unbiased analysis on global small molecule API for the forecast period of 2021 to 2031. In order to gain better perspective on its trends, drivers and challenges that the market is likely to witness in the upcoming years, the market is segmented on the basis of molecule type (standard API and HPAPI), production (captive/in house, and outsource), application (clinical, and commercial), therapeutic area (cardiovascular disease, respiratory disease, infectious disease, metabolic disorder, oncology, immunology, neurology, urology, dermatology, ophthalmology, general health and others), and region (North America, Latin America, East Asia, South Asia, Oceania and Middle East & Africa).
Download Complete TOC Of this Report @ https://www.futuremarketinsights.com/toc/rep-gb-4591
Explore FMI’s Extensive Coverage on Healthcare Domain
Prefilled Syringes Drug Molecules Market: The global prefilled syringes drug molecules market report by FMI gives an in-depth insight on the future expansion prospects, trends and challenges that market is likely to face in the upcoming decade. Key statistics regarding key segments have been presented across prominent geographies, along with a detailed assessment of the market’s competitive landscape.
Injectable Drug Delivery Market: Future Market Insights gives a detailed segmentation on the global injectable drug delivery market with upcoming market trends, challenges and future growth dynamics across key geographies and prominent segments. The report provides a holistic approach, mapping the competitive landscape with detailed analysis on established players, new entrants, and opportunities likely to prevail across the 2021-2031 decade.
Generic Injectable Market: The generic injectable market study published by FMI offers a comprehensive analysis and focused views on major trends expected to provide shape to future growth prospects. The report provides detailed analysis of the significant drivers, trends, challenges and opportunities prevailing for the forthcoming decade across key geographies along with competitive landscape of the upcoming decade.
About Future Market Insights (FMI)
Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, and has delivery centers in the UK, U.S. and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.
Contact:
Mr. Abhishek Budholiya
Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
MARKET ACCESS DMCC Initiative
For Sales Enquiries: sales@futuremarketinsights.com
For Media Enquiries: press@futuremarketinsights.com
Report: https://www.futuremarketinsights.com/reports/small-molecule-api-market
Press Release Source: https://www.futuremarketinsights.com/press-release/small-molecule-api-market
SOURCE: Future Market Insights
View source version on accesswire.com:
https://www.accesswire.com/641754/Small-Molecule-API-Market-to-Gain-Pace-as-Government-Spending-on-Novel-Biologics-Research-Increases-FMI
